Kidney study reveals how opemalirsen behaves in the body
NCT ID NCT07154901
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study looked at how the drug opemalirsen (AZD2373) is processed in people with different levels of kidney function. Researchers gave a single injection to 35 adults, some with kidney impairment and some with healthy kidneys. The goal was to compare drug levels and safety, helping guide future dosing for patients with kidney problems.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- opemalirsen (AZD2373)
- What this could lead to
- If successful, this could help doctors understand how to dose opemalirsen safely for people with kidney impairment.
- What could go wrong
- This is a very early, small study (35 people) that only looks at drug levels, not whether the drug works for any disease. Results may not apply to larger populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Miami, Florida, 33172, United States
-
Research Site
Orlando, Florida, 32808, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Aging kidneys under the microscope: could a simple test predict failure?
- Could your gut bacteria hold the key to protecting your kidneys?
- Food as medicine: could cooking classes slow kidney disease?
- Can a damaged kidney change how antibiotics work?
- Could a phone app be the key to managing kidney disease?
- A new pill aims to slow kidney failure and save lives